Humana (HUM)
(Delayed Data from NYSE)
$279.45 USD
-37.29 (-11.77%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $278.50 -0.95 (-0.34%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$279.45 USD
-37.29 (-11.77%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $278.50 -0.95 (-0.34%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth F Momentum D VGM
Zacks News
Humana (HUM) Teams Up With DME Entities to Boost Home Solutions
by Zacks Equity Research
These partnerships will equip Humana (HUM) with the means to deploy advanced clinical programs that can reduce hospitalizations for the members.
Here's Why Humana (HUM) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Select Medical (SEM) Q1 Earnings Top on Improving Profitability
by Zacks Equity Research
Select Medical (SEM) expects revenues to be within the range of $6.5-$6.7 billion in 2023, indicating a rise of 4.8% from the 2022 figure of $6.3 billion.
Brokers Suggest Investing in Humana (HUM): Read This Before Placing a Bet
by Zacks Equity Research
The average brokerage recommendation (ABR) for Humana (HUM) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Molina Healthcare (MOH) Beats on Q1 Earnings, Ups '23 EPS View
by Zacks Equity Research
Molina Healthcare's (MOH) Q1 results reflect strong performance in the Medicaid and Medicare segments. Meanwhile, the elevated expense level partially offset the positives.
Tenet Healthcare's (THC) Q1 Earnings Beat, Shares Up 3.9%
by Zacks Equity Research
Tenet Healthcare's (THC) first-quarter 2023 results gain on increased patient volumes. Management presently expects adjusted EPS within $4.92-$6.09 in 2023, up from the prior view of $4.68-$5.85.
Humana (HUM) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
Although the revenue and EPS for Humana (HUM) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Humana (HUM) Q1 Earnings Beat on Growing Membership & Premiums
by Zacks Equity Research
Humana (HUM) expects adjusted EPS to be at least $28.25 in 2023, up from the previous guidance of $28 per share.
Humana (HUM) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Humana (HUM) delivered earnings and revenue surprises of 1.41% and 1.61%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights Humana, Viatris, agilon health and Cano Health
by Zacks Equity Research
Humana, Viatris, agilon health and Cano Health are included in this Analyst Blog.
Zacks.com featured highlights Marcus, AssetMark Financial, Humana, Riely Exploration Permian and ICF International
by Zacks Equity Research
Marcus, AssetMark Financial, Humana, Riely Exploration Permian and ICF International have been highlighted in this Screen of The Week article.
Ecolab (ECL) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Ecolab's (ECL) first-quarter results are likely to reflect continued strength in its Global Industrial segment.
4 Healthcare Stocks Poised to Beat Q1 Earnings Estimates
by Kaibalya Pravo Dey
Growing patient volumes, admissions, health awareness and technological improvement in the first quarter are likely to have aided healthcare players like Humana (HUM), Viatris (VTRS), agilon health (AGL) and Cano Health (CANO).
Buy These 5 Low Leverage Stocks Ahead of Big Earnings Releases
by Aparajita Dutta
The crux of safe investment lies in choosing a company that is not burdened with debt as a debt-free stock is almost impossible to find. You may buy MCS, AMK, HUM, REPX and ICFI.
Is a Surprise Coming for Humana (HUM) This Earnings Season?
by Zacks Equity Research
Humana (HUM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Will Humana's (HUM) Q1 Earnings Beat on Insurance Unit Strength?
by Zacks Equity Research
Humana's (HUM) first-quarter results are likely to reflect surging premiums and investment income.
What's in Store for Molina Healthcare (MOH) in Q1 Earnings?
by Zacks Equity Research
Molina Healthcare's (MOH) Q1 results are likely to have benefited from the strong performance of its Medicaid and Medicare businesses, partly offset by rising operating costs.
Humana (HUM) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Humana (HUM) closed the most recent trading day at $491.21, moving +0.18% from the previous trading session.
Universal Health (UHS) to Release Q1 Earnings: Factors to Note
by Zacks Equity Research
Universal Health's (UHS) Q1 results are likely to benefit from higher patient volumes and solid demand for behavioral healthcare services. However, increased labor costs might partly offset the results.
Humana (HUM) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Humana (HUM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Investors Undervaluing Humana (HUM) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Humana (HUM) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Humana (HUM) closed at $518.82 in the latest trading session, marking a -0.96% move from the prior day.
UnitedHealth (UNH) Buys Crystal Run to Boost Value-Based Care
by Zacks Equity Research
UnitedHealth Group (UNH) acquires Crystal Run, as per multiple reports. The move tends to offer enhanced value-based care across the Hudson Valley and lower Catskill region.
Wall Street Bulls Look Optimistic About Humana (HUM): Should You Buy?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Humana (HUM). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?